Hereditary Cancer Diagnostics: The Clinical Impact of Variant Reclassification

Scott Turner, Ph.D.
Clinical Molecular Genetics Fellow
Vanderbilt University Medical Center

At the conclusion of this activity, the participant will be able to:

1. Compare the efficacy of recent variant interpretation guidelines across multiple laboratories
2. Recognize the clinical impact of variant reclassification on the management of patients at risk of hereditary cancer syndromes
3. Identify the need for improved methodologies for more timely reinterpretation of genetic data

Accreditation: VCU Health Continuing Medical Education of Virginia Commonwealth University Health System is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Credit Designation: VCU Health Continuing Medical Education of Virginia Commonwealth University Health System designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Financial Relationships:
The following planners, moderators or speakers have the following financial relationship(s) with commercial interests to disclose: Nothing to disclose